Clinical trials
PD-L1 clinical trials
Below are recruiting pd-l1 clinical trials, each written for real people, not researchers. We’re tracking 107 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05777824RecruitingPhase 2
Testing treatment after head and neck cancer response to chemo-immunotherapy
This Phase 2 study looks at what treatment is best after you first receive chemotherapy plus immunotherapy, then have surgery for head and neck squamous cell cancer. It tries to use how your tumor responds (shown in lab tissue after treatment) to guide the next steps, which may improve outcomes.
Beijin, Beijing MunicipalityAges 18–75 - NCT07863999RecruitingPhase 3
Immunotherapy before surgery for stage II-III lung cancer
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
Shanghai, ChinaAges 18 years+ - NCT06345287RecruitingPhase 2
Adaptive radiotherapy after immunotherapy for head and neck cancer
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
BeijingAges 18–75 - NCT07781358RecruitingPhase 2
Testing a new drug combination for recurrent nasopharyngeal cancer
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07775820Recruiting
Retrying immunotherapy after lung inflammation
This trial looks at whether people with lung cancer who had lung inflammation from immunotherapy can safely try immunotherapy again. It aims to see if restarting treatment helps without causing severe side effects.
Guangzhou, GuangdongAges 18 years+ - NCT06259552RecruitingPhase 1
Study of SPX-303 for advanced solid tumors
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT07744698RecruitingPhase 4
Maintenance therapy for advanced lung cancer
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hefei, AnhuiAges 18–75 - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+ - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75 - NCT06084286RecruitingPhase 1
CAR-T therapy targeting CLDN18.2 and PD-L1 for advanced solid tumors
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Chengdu, SichuanAges 18–75 - NCT07637474Recruiting
Immune System and Lung Cancer Response to Immunotherapy
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
Rome, RomeAges 18 years+ - NCT06301399RecruitingPhase 2
Rituximab with prior therapy for advanced liver cancer
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 17–79 - NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07618936Recruiting
PD-L1 PET/CT imaging scan for cancer patients
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
Hefei, AnhuiAges 18–80 - NCT06742424RecruitingPhase 2
PD-L1 antibody + bevacizumab + liver chemo for advanced liver cancer
This trial tests whether combining a PD-L1 antibody (an immunotherapy) with bevacizumab (a drug that slows blood vessel growth to tumors) and a liver-directed chemotherapy infusion can help people with advanced liver cancer that has spread outside the liver. It is designed for patients who have not previously received these specific treatments.
Chengdu, SichuanAges 18–75 - NCT07523737RecruitingPhase 2
Combination drug trial for relapsed brain lymphoma
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07472153RecruitingPhase 2/Phase 3
Immunotherapy plus chemo for advanced cervical cancer
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Minsk, LesnoyAges 18–75 - NCT07444437RecruitingPhase 2
LM103 after surgery for lung cancer
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
Guangzhou, GuangdongAges 18–75 - NCT07396259Recruiting
PD-L1 test in blood to predict immunotherapy success
This trial is monitoring changes in a cancer protein called PD-L1 in head and neck cancer patients before and during immunotherapy treatment. It aims to better understand how well immunotherapy will work by using regular blood tests.
Taoyuan, CityAges 18 years+ - NCT07373964RecruitingPhase 2
Study of new drug combo for extensive-stage small-cell lung cancer
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
Shenyang, LiaoningAges 18–75 - NCT06869239Recruiting
Predicting response to PD-L1 inhibitor after chemoradiotherapy for limited-stage small cell lung cancer
This study uses a blood test to see if it can predict how well the PD-L1 inhibitor (an immunotherapy drug) works after standard chemotherapy and radiation for limited-stage small cell lung cancer. It aims to find better ways to match treatment to patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT07312422RecruitingPhase 1/Phase 2
Low-dose radiation with immunotherapy and standard therapy for advanced pancreatic cancer
This trial combines low-dose radiation with an immunotherapy drug (pucotenlimab) and standard treatment for advanced pancreatic cancer. It aims to see if this triple therapy can help control the cancer without using a PD-1/PD-L1 inhibitor before.
Hangzhou, ZhejiangAges 18–75 - NCT06635954Recruiting
Blood test to predict response to immunotherapy
This study is testing a blood test (Episwitch CiRT®) that looks at your DNA to see if it can predict whether you will respond to a type of immunotherapy called PD-(L)-1 checkpoint inhibitors. The goal is to see if this test is accurate across many different types of cancer.
Norwich, ConnecticutAges 18 years+ - NCT07293754RecruitingPhase 1/Phase 2
Study of RPTR-1-201 for advanced solid tumors
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+
Hear when a new PD-L1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pd-l1?
- Yes. Clin2 currently lists 107 recruiting pd-l1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pd-l1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pd-l1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.